CAReS Study Evaluating ART27.13 in Cancer Anorexia Progresses to Fourth Cohort ART26.12 Program to Target Chemotherapy-Induced Peripheral Neuropathy ...
Initiates Fourth Cohort at a 650-Microgram Dose with Data Expected in Q4 2022 ...
Presentation delivered by Professor Saoirse O’Sullivan at the 32nd Annual ICRS Symposium in Galway, Ireland on Sunday, June 26th...
Presentation delivered by Professor Saoirse O’Sullivan at the 32nd Annual ICRS Symposium in Galway, Ireland on Sunday, June 26th...
SOLANA BEACH, Calif., June 24, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on...
SOLANA BEACH, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. “Artelo” or the “Company”) (NASDAQ: ARTL), a clinical-stage...
RALEIGH, NC / ACCESSWIRE / May 16, 2022 / The Spring into Action- Best Ideas Virtual Investor Conference will take place on May 16th - 20th, 2022, where 36 SmallCap, MicroCap and NanoCap public companies...
SOLANA BEACH, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. “Artelo” or the “Company”) (NASDAQ: ARTL), a clinical stage...
SOLANA BEACH, CA / ACCESSWIRE / May 13, 2022 / Artelo Biosciences, Inc. "Artelo" or the "Company") (NASDAQ:ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate lipid-signaling...
$23.5 Million in Cash and Investments as of March 31, 2022, Expected to Support Completion of the CAReS Trial and Operations Into Second Half of 2023 ...